Effectiveness of sotalol treatment in symptomatic Brugada syndrome.
We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.
Glatter
Kathryn A
KA
University of California-San Francisco, San Francisco, CA, USA. kaglatter@ucdavis.edu
Wang
Qing
Q
Keating
Mark
M
Chen
Shenghan
S
Chiamvimonvat
Nipavan
N
Scheinman
Melvin M
MM
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004562:Electrocardiography; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D013015:Sotalol / Q000627:therapeutic use*; D013577:Syndrome; D014693:Ventricular Fibrillation / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D013015:Sotalol